'Human foie gras' whets appetite of drugs giants

June 15, 2017

As obesity expands waistlines in the Western world, a silent killer linked to the condition nicknamed "human foie gras" is spurring a potential bonanza worth billions for drugs giants.

The disease, formally known as non-alcoholic steatohepatitis (NASH), is caused by a buildup of fat in the . It is already the leading ailment cited in requests for in the United States, Cecile Rabian of France's Gilead laboratory told AFP.

"We imagine that this will also be the case in Europe very soon," she added.

The GlobalData research group estimates that NASH could underpin a market worth more than $25 billion (22 billion euros) by 2026.

And the market should grow by a healthy 45 percent each year in the initial phases of the rollout of drugs to counter the disease, GlobalData says—with the main customer base in the United States, western Europe and Japan.

Epidemiological studies suggest that 12 percent of Americans and six percent of Europeans already suffer from the condition.

Abnormal fat accumulation

NASH can lead to scarring of the liver, which in turn leads to cirrhosis.

Abnormal accumulation of fat in the liver can set off the first stage of the disease, characterised by a chronic inflammation of the liver.

Fatty liver in ducks and geese produces the prized French delicacy of foie gras—a natural phenomenon with migrating birds that is controversially replicated by poultry farmers who force-feed their fowl.

In humans, the inflammation slowly eats away at the liver's cells, causing scar tissue to form known as fibrosis.

This can result in either or what is known as non-alcoholic cirrhosis of the liver.

NASH recently hit the headlines in France when a sports journalist suffering from the disease received a double liver and kidney transplant.

The pharmaceuticals giants began ramping up their response to NASH in 2015.

US giant Allergan acquired Californian biotech firm Tobira for $1.7 billion last year, and recently hooked up with Switzerland's Novartis to carry out clinical trials.

Danish diabetes giant Novo Nordisk is also interested—among many others.

"Since NASH goes through several stages, it will probably be necessary to bring together several action mechanisms—bi-therapies or tri-therapies—to try to be even more effective," Rabian said.

Final trials

Three companies are leading the pack, with candidate drugs already in the final third phase of development: Gilead, US firm Intercept and French biotech firm Genfit.

Shares in Genfit, based in the northern French city of Lille, have skyrocketed amid acquisition rumours, and the company's value now exceeds 900 million euros.

"There's still a very high probability of being acquired by a big pharmaceutical group," Genfit's CEO Jean-Francois Mouney told AFP. "But we're not idly waiting for customers to knock on our door, we're moving forward. And the more we move ahead, the more we are attracting attention."

The preliminary results of the phase-three trials are expected in mid-2019 for Genfit's drug Elafibranor, which is designed to reduce if not halt inflammation and degeneration of .

The drug targets two receptors in the cell's nucleus that regulate the genes that are key to its functioning.

Mouney hopes the green light will come for the drug to go on the market in Europe and the United States by the end of 2019 or early 2020.

For now health authorities have approved only one diagnostic tool for NASH—a biopsy of liver tissue, which is a costly procedure, difficult to implement on a large scale and not without risk for the patient.

Prevention

The industry is looking to develop diagnostic tools for NASH such as blood tests or imaging techniques, without which the market will face a "bottleneck", Arnaud Guerin, an analyst with the brokerage firm Portzamparc, told AFP.

The market should eventually rival that of oral anti-diabetes drugs, which cost $13,000-15,000 annually in the United States— about half that in Europe, Mouney said.

Some laboratories have mooted an annual cost of up to $50,000 per NASH patient.

According to the New England Journal of Medicine, 30 percent of the world's population was overweight in 2015.

In view of the increase in NASH sufferers, health authorities say prevention is the best cure, and also the cheapest: a low-sugar diet accompanied by regular exercise.

etb/gd/jj

Explore further: Diet and exercise can improve kidney function in patients with fatty liver disease

Related Stories

Diet and exercise can improve kidney function in patients with fatty liver disease

November 21, 2016
Non-alcoholic steatohepatitis (NASH) is a potentially serious liver condition characterized by excess fat in the liver associated with inflammation and scarring. NASH may progress to cirrhosis of the liver and liver cancer, ...

Fatty liver: Turning off TAZ reverses disease

October 27, 2016
Scientists at Columbia University Medical Center (CUMC) have identified a factor in liver cells that is responsible for turning a relatively benign liver condition, present in 30 percent of U.S. adults, into a serious disease ...

Simple blood test could vastly improve detection rates of severe liver disease

October 6, 2016
A new non-invasive method of predicting the risk of developing a severe form of liver disease could ensure patients receive early and potentially life-saving medical intervention before irreversible damage is done.

Inflammatory signature of nonalcoholic fatty liver disease

May 16, 2017
A team of investigators led by Rohit Kohli, MBBS, MS, of Children's Hospital Los Angeles, has identified key inflammatory cells involved in nonalcoholic fatty liver disease. Current treatment for the disorder involves changes ...

NASH associated with a 50 percent higher chance of death compared with NAFLD

April 24, 2015
Results from a large population-based cohort of almost a million people in the UK found that the chances of dying from non-alcoholic steatohepatitis (NASH), over a 14-year period, was approximately 50% higher than for those ...

Existing diabetes drug shows effectiveness against chronic liver disease

June 21, 2016
Researchers have found that an existing diabetes drug can be used to halt progression of another disease that is a leading cause of liver transplants.

Recommended for you

Zika virus stifles pregnant women's weakened immune system to harm baby, study finds

August 21, 2017
The Zika virus, linked to congenital birth defects and miscarriages, suppresses a pregnant woman's immune system, enabling the virus to spread and increasing the chances an unborn baby will be harmed, a Keck School of Medicine ...

Fatty liver can cause damage to other organs via crosstalk

August 21, 2017
Nonalcoholic fatty liver disease is increasingly common. Approximately every third adult in industrialized countries has a morbidly fatty liver. This not only increases the risk of chronic liver diseases such as liver cirrhosis ...

Faulty gene linked to obesity in adults

August 18, 2017
Groundbreaking new research linking obesity and metabolic dysfunction to a problem in the energy generators in cells has been published by researchers from the Harry Perkins Institute of Medical Research and The University ...

Two lung diseases killed 3.6 million in 2015: study

August 17, 2017
The two most common chronic lung diseases claimed 3.6 million lives worldwide in 2015, according to a tally published Thursday in The Lancet Respiratory Medicine.

New test differentiates between Lyme disease, similar illness

August 16, 2017
Lyme disease is the most commonly reported vector-borne illness in the United States. But it can be confused with similar conditions, including Southern Tick-Associated Rash Illness. A team of researchers led by Colorado ...

Addressing superbug resistance with phage therapy

August 16, 2017
International research involving a Monash biologist shows that bacteriophage therapy – a process whereby bacterial viruses attack and destroy specific strains of bacteria - can be used successfully to treat systemic, multidrug ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.